GC6 – Micro-ultrasound-guided versus MRI-guided biopsy for prostate cancer diagnosis (OPTIMUM trial)
L.H. Klotz, A. Kinnaird, Hannes Cash(Royal Free London NHS Foundation Trust), Christopher Fung(University of Alberta), Giovanni Lughezzani(Humanitas University), Salah Ouertani, Sangeet Ghai(University Health Network), Niklas Harland(STZ eyetrial), Weichao Tu(West Virginia University), F. Gomez-Sancha, Petr Macek(Institute Mutualiste Montsouris), Julian P. Struck(Atotech (Germany)), Andreas Gusenleitner(Krankenhaus der Elisabethinen), C. Pavlovich, Wayne Brisbane(University of California, Los Angeles), Ferdinand Luger(Krankenhaus der Elisabethinen), H. Toledano, Martin Schostak(Aturo), Neal D. Shore(Carolina Urologic Research Center), Joseph Renzulli(Yale University), Luis Felipe Urdaneta-Salegui(Clinic IMQ Zorrotzaurre)
Cited by 0
Related Papers
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
|Clinical Cancer Research|2017|635
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
|New England Journal of Medicine|2020|442